OBJECTIVE: In this study, we investigated whether dyslipidemia-associated perturbed invariant natural killer T (iNKT) cell function is due to intrinsic changes in iNKT cells or defects in the ability of antigen-presenting cells to activate iNKT cells. METHODS AND RESULTS: We compared iNKT cell expansion and cytokine production in C57BL/6J (B6) and apolipoprotein E-deficient (apoE(-/-)) mice. In response to in vivo stimulation with alpha-galactosylceramide, a prototypic iNKT cell glycolipid antigen, apoE(-/-) mice showed significantly decreased splenic iNKT cell expansion at 3 days after injection, a profile associated with iNKT cell anergy due to chronic stimulation. This decrease in expansion and cytokine production was accompanied by a 2-fold increase in percentage of iNKT cells expressing the inhibitory marker programmed death-1 in apoE(-/-) mice compared with controls. However, in vivo and in vitro blockade of programmed death-1 using monoclonal antibody was not able to restore functions of iNKT cells from apoE(-/-) mice to B6 levels. iNKT cells from apoE(-/-) mice also had increased intracellular T cell receptor and Ly49 expression, a phenotype associated with previous activation. Changes in iNKT cell functions were cell autonomous, because dendritic cells from apoE(-/-) mice were able to activate B6 iNKT cells, but iNKT cells from apoE(-/-) mice were not able to respond to B6 dendritic cells. CONCLUSIONS: These data suggest that chronic dyslipidemia induces an iNKT cell phenotype that is unresponsive to further simulation by exogenous glycolipid and that sustained unresponsiveness is iNKT cell intrinsic.
OBJECTIVE: In this study, we investigated whether dyslipidemia-associated perturbed invariant natural killer T (iNKT) cell function is due to intrinsic changes in iNKT cells or defects in the ability of antigen-presenting cells to activate iNKT cells. METHODS AND RESULTS: We compared iNKT cell expansion and cytokine production in C57BL/6J (B6) and apolipoprotein E-deficient (apoE(-/-)) mice. In response to in vivo stimulation with alpha-galactosylceramide, a prototypic iNKT cell glycolipid antigen, apoE(-/-) mice showed significantly decreased splenic iNKT cell expansion at 3 days after injection, a profile associated with iNKT cell anergy due to chronic stimulation. This decrease in expansion and cytokine production was accompanied by a 2-fold increase in percentage of iNKT cells expressing the inhibitory marker programmed death-1 in apoE(-/-) mice compared with controls. However, in vivo and in vitro blockade of programmed death-1 using monoclonal antibody was not able to restore functions of iNKT cells from apoE(-/-) mice to B6 levels. iNKT cells from apoE(-/-) mice also had increased intracellular T cell receptor and Ly49 expression, a phenotype associated with previous activation. Changes in iNKT cell functions were cell autonomous, because dendritic cells from apoE(-/-) mice were able to activate B6 iNKT cells, but iNKT cells from apoE(-/-) mice were not able to respond to B6 dendritic cells. CONCLUSIONS: These data suggest that chronic dyslipidemia induces an iNKT cell phenotype that is unresponsive to further simulation by exogenous glycolipid and that sustained unresponsiveness is iNKT cell intrinsic.
Authors: Paul A VanderLaan; Catherine A Reardon; Yuval Sagiv; Lydia Blachowicz; John Lukens; Michael Nissenbaum; Chyung-Ru Wang; Godfrey S Getz Journal: Am J Pathol Date: 2007-03 Impact factor: 4.307
Authors: Sungjune Kim; Saif Lalani; Vrajesh V Parekh; Tiffaney L Vincent; Lan Wu; Luc Van Kaer Journal: J Clin Invest Date: 2008-06 Impact factor: 14.808
Authors: E John Wherry; Sang-Jun Ha; Susan M Kaech; W Nicholas Haining; Surojit Sarkar; Vandana Kalia; Shruti Subramaniam; Joseph N Blattman; Daniel L Barber; Rafi Ahmed Journal: Immunity Date: 2007-10-18 Impact factor: 31.745
Authors: Stephan D Gadola; Jonathan D Silk; Aruna Jeans; Petr A Illarionov; Mariolina Salio; Gurdyal S Besra; Raymond Dwek; Terry D Butters; Frances M Platt; Vincenzo Cerundolo Journal: J Exp Med Date: 2006-09-18 Impact factor: 14.307
Authors: Karl O A Yu; Jin S Im; Petr A Illarionov; Rachel M Ndonye; Amy R Howell; Gurdyal S Besra; Steven A Porcelli Journal: J Immunol Methods Date: 2007-04-05 Impact factor: 2.303
Authors: Eleanor Clancy-Thompson; Lestat Ali; Patrick T Bruck; Mark A Exley; Richard S Blumberg; Glenn Dranoff; Michael Dougan; Stephanie K Dougan Journal: Cancer Immunol Res Date: 2017-11-29 Impact factor: 11.151
Authors: Gerhard Wingender; Marcus Hiss; Isaac Engel; Konrad Peukert; Klaus Ley; Hermann Haller; Mitchell Kronenberg; Sibylle von Vietinghoff Journal: J Immunol Date: 2012-03-02 Impact factor: 5.422
Authors: Xiufang Weng; Amrendra Kumar; Liang Cao; Ying He; Eva Morgun; Lavanya Visvabharathy; Jie Zhao; Laura A Sena; Sam E Weinberg; Navdeep S Chandel; Chyung-Ru Wang Journal: Proc Natl Acad Sci U S A Date: 2021-03-30 Impact factor: 11.205
Authors: Paul A VanderLaan; Catherine A Reardon; Veneracion G Cabana; Chyung-Ru Wang; Godfrey S Getz Journal: Int J Mol Sci Date: 2019-09-14 Impact factor: 6.208